References
- Agrawal A, Shrive AK, Greenhough TJ, Volanakis JE. Topology and structure of the C1q-binding site on CRP. J Immunol 2001; 166(6)3998–4004
- Vogt B, Fuhrnrohr B, Muller R, Sheriff A. CRP and the disposal of dying cells: Consequences for SLE and RA. Autoimmunity 2007; 40(4)295–298
- Gershov D, Kim S, Brot N, Elkon KB. CRP binds to apo cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: Implications for systemic autoimmunity. J Exp Med 2000; 192(9)1353–1364
- Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW. CRP binds to FcγRI in transfected COS cells. J Immunol 1995; 155(4)2185–2193
- Du Clos TW, Zlock LT, Rubin RL. Analysis of the binding of CRP to histones and chromatin. J Immunol 1988; 141(12)4266–4270
- Elkon KB. Apo in SLE: Too little or too much?. Clin Exp Rheumatol 1994; 12(5)553–559
- Becker GJ, Waldburger M, Hughes GR, Pepys MB. Value of serum CRP measurement in the investigation of fever in SLE. Ann Rheum Dis 1980; 39(1)50–52
- Sjowall C, Eriksson P, Almer S, Skogh T. AAb to CRP is a common finding in SLE, but not in primary SS, RA or inflammatory bowel disease. J Autoimmun 2002; 19(3)155–160
- Szalai AJ, Weaver CT, McCrory MA, van Ginkel FW, Reiman RM, Kearney JF, et al. Delayed lupus onset in (NZB × NZW)F1 mice expressing a human CRP transgene. Arthritis Rheum 2003; 48(6)1602–1611
- Chitrabamrung S, Rubin RL, Tan EM. Serum DNase I and clinical activity in SLE. Rheumatol Int 1981; 1(2)55–60